Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., trading under the SPAC ticker LACQ (Leisure Acquisition Corp.), filed a 10-Q with the SEC on November 9, 2020, reflecting the company's status as a blank-check vehicle that had announced a business combination with Ensysce Biosciences, a clinical-stage pharmaceutical company focused on abuse-deterrent opioid and stimulant formulations. Leisure Acquisition Corp. completed its IPO in 2019, originally targeting the leisure and gaming sector before pivoting to healthcare through the Ensysce transaction. The merger ultimately closed in 2021, bringing Ensysce to the public markets through the SPAC structure. For complete filing history, deal terms, and PIPE details on LACQ and thousands of other SPAC transactions, sign up for full data access at SpacDesk.